Cancer Biology and Therapeutics (CBT)

项目概要/摘要：癌症生物学和治疗学 癌症生物学和治疗学（CBT）计划汇集了37名教师，代表12个部门 在达特茅斯的盖泽尔医学院（盖泽尔），其瓜里尼研究生院和高级研究， 达特茅斯-希区柯克医学中心（DH），研究兴趣与三个中心CBT计划有关 主题：1）癌细胞信号传导和代谢，2）细胞周期生物学和基因组稳定性，3）染色质 生物学和致癌转录。CBT计划的共同目标是：i）推进 了解癌症发生、发展和转移的基本机制，以支持 癌症的预防、诊断和治疗; ii）确定和验证新的途径和分子靶点， 有效治疗干预; iii）促进双向翻译以开发和改进新的 治疗和诊断策略。同行评审的癌症相关研究直接费用支持目前 总计700万美元，NCI资金占25%（180万美元），直接成本总额为790万美元。二十（20） CBT计划成员目前共有28个CCSG定义的R 01等效奖项。使用相同的 2014年癌症相关直接成本的定义（即，不包括所有间接和培训， 行政直接成本），同行评审的癌症相关研究直接成本（700万美元）比2010年增加了14%。 2014年，癌症机制和分子治疗的结合（610万美元）。自2015年以来，CBT 该计划有446篇癌症相关出版物，22%（98篇）是计划内出版物，24%（109篇）是计划间出版物， 52%（232）来自其他机构的研究者，24%（97）来自高影响力期刊（即，影响因子 >8）。与2014年癌症机制和分子治疗学的结合相比， 计划出版物从15%增加到22%，沿着增加的还有计划间出版物（从2008年增加到24%）。 21%）和高影响力（从22%降至24%）。CBT计划将继续 通过建立和加强多学科合作，实现拟议的具体目标， 基础、转化和临床研究人员，指导初级教员实现学术独立， 促进临床医生和实验室科学家的伙伴关系，推动研究人员的发展， 启动临床研究。

Project Summary/Abstract: Cancer Biology and Therapeutics The Cancer Biology and Therapeutics (CBT) Program brings together 37 faculty, representing 12 departments at Dartmouth’s Geisel School of Medicine (Geisel), its Guarini School of Graduate and Advanced Studies, and the Dartmouth-Hitchcock Medical Center (DH), with research interests relevant to three central CBT Program themes: 1) Cancer cell signaling and metabolism, 2) Cell cycle biology and genome stability, and 3) Chromatin biology and oncogenic transcription. The shared goals of the CBT Program are to: i) advance the understanding of the basic mechanisms that underlie cancer initiation, progression, and metastasis to support prevention, diagnosis and treatment of cancer; ii) identify and validate new pathways and molecular targets for effective therapeutic intervention; iii) facilitate bi-directional translation to develop and improve novel therapeutic and diagnostic strategies. Peer-reviewed cancer-related research direct cost support currently totals $7.0M, with NCI funding representing 25% ($1.8M) and total direct costs summing to $7.9M. Twenty (20) CBT Program Members currently have a total of 28 CCSG-defined R01-equivalent awards. Using the same definition of cancer-related direct costs in 2014 (i.e., excluding all indirects as well as training and administrative direct costs), peer-reviewed cancer-related research direct costs ($7.0M) are up 14% compared to the combination of Cancer Mechanisms and Molecular Therapeutics in 2014 ($6.1M). Since 2015, the CBT Program has 446 cancer-related publications, 22% (98) intra-programmatic, 24% (109) inter-programmatic, 52% (232) with investigators from other institutions, and 24% (97) in high impact journals (i.e., impact factor >8). Compared to the combination of Cancer Mechanisms and Molecular Therapeutics in 2014, intra- programmatic publications have increased, to 22% from 15%, along with inter-programmatic (to 24% from 21%) and high impact (to 24% from 22%) in the current reporting period. The CBT Program will continue to pursue the proposed Specific Aims through building and strengthening multidisciplinary collaborations between basic, translational, and clinical researchers, mentorship of junior faculty members to academic independence, and promotion of partnerships of clinicians and laboratory scientists to drive the development of investigator- initiated clinical studies.